


Product Name : INCB086550
Cat. No. : PC-72848
CAS No. : 2230911-59-6
Molecular Formula : C₄₁H₃₉N₇O₄
Molecular Weight : 693.808
Target : PD-1/PD-L1
Solubility : 10 mM in DMSO



Biological Activity

INCB086550 (INCB 86550) is a potent, selective small-molecule inhibitor of **PD-L1**, inhibits PD-L1/PD-1 interaction with IC₅₀ of 3.1, 4.9 and 1.9 nM for human, cynomolgus and rat PD-L1 in HTRF-based assays.

INCB086550 inhibited binding of phycoerythrin (PE)-labeled PD-1 (PD-1/PE) to cell surface PD-L1 with IC₅₀ of 13 nM.

INCB086550 blocked binding of the clinical anti-PD-L1 monoclonal antibodies (mAbs), atezolizumab and durvalumab, to PD-L1, potently and selectively binds to PD-L1 at a site that overlaps with the clinical anti-PD-L1 mAbs.

INCB086550 binds to PD-L1 and interrupts its interaction with PD-1 and also induces PD-L1 dimerization and internalization.

INCB086550 effectively restored NFAT pathway activation and abolished SHP recruitment to PD-1, thereby demonstrating functional inhibition of the PD-L1/PD-1 signaling pathway.

INCB086550 dose-dependently reduced unoccupied cell surface PD-L1 on the tumor cell surface in vivo, effectively inhibited tumor growth as a single agent in multiple humanized tumor models and was well tolerated.

INCB086550 reduced tumor growth in CD34+ humanized mice and induced T-cell activation gene signatures, consistent with PD-L1/PD-1 pathway blockade in vivo.

Oral administration of INCB086550 provides dose-related pharmacodynamic immune activation similar to that reported for PD-L1 or PD-1 therapeutic antibodies.

References

Holly K Koblish, et al. *Cancer Discov.* 2022 Mar 7; candisc.1156.2021.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com